DM is an independent risk factor for the development of HF and its presence confers an adverse prognosis for those already diagnosed with HF.TZDs are potent insulin-sensitisers associated with a number of beneficial cardiovascular effects. However,TZDs increase renal sodium and water reabsorption, leading to fluid retention and overt signs of HF in patients with diabetes. Rosiglitazone has also been associated with an increased risk of myocardial infarction and cardiovascular mortality. However, pioglitazone may have macrovascular benefits. The majority of data on the cardiovascular safety of TZDs are based on non-cardovascular outcome trials and meta-analyses. Concerns regarding the risk of HF and cardiovascular safety of TZDs have led to restrictions on their use in patients with HF. This review addresses the latest evidence for HF with each of the TZD drugs currently available and reflects on the current guidelines regarding their prescription in at-risk patients.
McMurray, JJ , Stewart, S. (2000) Epidemiology, aetiology, and prognosis of heart failure. Heart83: 596-602.
2.
Cowie, CC, Rust, KF, Byrd-Holt, DD, et al. (2006) Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care29: 1263-8.
3.
Iribarren, C. , Karter, AJ, Go, AS, et al. (2001) Glycemic control and heart failure among adult patients with diabetes. Circulation103: 2668-73.
4.
Shindler, DM , Kostis, JB, Yusuf, S., et al. (1996) Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol77: 1017-20.
5.
UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet352: 837-53.
6.
Patel, A., MacMahon, S., Chalmers, J., et al. (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med358: 2560-72.
7.
Swan, JW, Anker, SD, Walton, C., et al. (1997) Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol30: 527-32.
8.
Boudina, S., Abel, ED (2007) Diabetic cardiomyopathy revisited. Circulation115: 3213-23.
9.
Vasudevan, AR , Balasubramanyam, A. (2004) Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther6: 850-63.
10.
Diep, QN, El Mabrouk, M., Cohn, JS, et al. (2002) Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation105: 2296-302.
11.
Mazzone, T., Meyer, PM, Feinstein, SB, et al. (2006) Effect of pioglitazone compared with glimepiride on carotid intimamedia thickness in type 2 diabetes: a randomized trial. JAMA296: 2572-81.
12.
Guan, Y., Hao, C., Cha, DR, et al. (2005) Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med11: 861-6.
13.
Zhang, H., Zhang, A., Kohan, DE, et al. (2005) Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA102: 9406-11.
14.
Lincoff, AM, Wolski, K., Nicholls, SJ, et al. (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA298: 1180-8.
15.
Giles, TD, Miller, AB, Elkayam, U., et al. (2008) Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail14: 445-52.
16.
Nissen, SE, Wolski, K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med356: 2457-71.
17.
Dahabreh, IJ (2008) Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clin Trials5: 116-20.
18.
Singh, S., Loke, YK, Furberg, CD (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA298: 1189-95.
19.
Nesto, RW, Bell, D., Bonow, RO, et al. (2004) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care27: 256-63.
20.
Dagenais, GR , Gerstein, HC, Holman, R., et al. (2008) Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care31: 1007-14.
21.
Home, PD, Pocock, SJ, Beck-Nielsen, H., et al. (2007) Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med357: 28-38.
22.
Kahn, SE, Haffner, SM, Heise, MA, et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide mono-therapy. N Engl J Med355: 2427-43.
23.
Gerstein, HC , Yusuf, S., Bosch, J., et al. (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet368: 1096-105.
24.
Lago, RM, Singh, PP, Nesto, RW (2007) Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet370: 1129-36.
25.
Dormandy, JA , Charbonnel, B., Eckland, DJ, et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet366: 1279-89.
26.
Home, PD, Pocock, SJ, Beck-Nielsen, H., et al. (2005) Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes (RECORD): study design and protocol . Diabetologia48: 1726-35.
27.
St. John Sutton, M., Rendell, M., Dandona, P., et al. (2002) A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care25: 2058-64.
28.
Dargie, HJ, Hildebrandt, PR, Riegger, GA, et al. (2007) A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol49: 1696-704.
29.
Turkmen Kemal, Y., Guvener Demirag , N., Yildirir, A., et al. (2007 ) Effects of rosiglitazone on plasma brain natriuretic peptide levels and myocardial performance index in patients with type 2 diabetes mellitus . Acta Diabetol44: 149-56.
30.
Erdmann, E. , Charbonnel, B., Wilcox, RG, et al. (2007) Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care30: 2773-8.
31.
Ogawa, S., Takeuchi, K., Ito, S. (2003) Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone. J Clin Endocrinol Metab88: 3993-6.
32.
Sambanis, C. , Tziomalos, K., Kountana, E., et al. (2008) Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes. Acta Diabetol45: 23-30.
33.
Krall, RL (2007) Cardiovascular safety of rosiglitazone. Lancet369: 1995-6.
34.
Lebovitz, HE , Banerji, MA (2001) Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res56: 265-94.
35.
Isley, WL (2003) Hepatotoxicity of thiazolidinediones. Expert Opin Drug Saf2: 581-6.
36.
Todorov, VT , Desch, M., Schmitt-Nilson , N., et al. (2007) Peroxisome proliferator-activated receptor-gamma is involved in the control of renin gene expression. Hypertension50: 939-44.
37.
Guan, Y., Zhang, Y., Davis, L., et al. (1997) Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol273: F1013-22.
38.
Zanchi, A., Chiolero, A., Maillard, M., et al. (2004) Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab89: 1140-5.
39.
Rosiglitazone and pioglitazone: cardiovascular safety. (2007) Drug Safety Update1: 5-6.
40.
Montori, VM , Gandhi, GY, Guyatt, GH (2007) Patient-important outcomes in diabetes - time for consensus. Lancet370: 1104-6.
